Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Country's Decision or any other Communication
(DEC)
last updated: 09 Jan 2014
No
Commercial release of a biological product for veterinary use, namely VECTORMUNE® FP-LT+AE- Fowl Pox and avian Laryngotracheitis vaccine and avian encephalomyelitis
EN
16 Jun 2011
No
- Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
No
Yes
-
Person:Dr Alexis Henry Gaetan GouxPresident of CIBio,Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrazilPhone: 551938337700,Fax: 55193833-7722,Email: alexisgoux@ceva.com,Website: http://www.ceva.com.br/,Related OrganizationCeva Saúde Animal Ltda (CEVA)Private sector (business and industry)Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrazilPhone: 551938337700,Fax: 55193833-7722,Email: alexisgoux@ceva.com,Website: http://www.ceva.com.br/,
No
Yes
No
Approval of the import and/or use of the LMO(s) without conditions
-
BCH-LMO-SCBD-105176-3 Living Modified Organism VECTORMUNE® FP-LT + AE VaccineCeva Saúde Animal Ltda(CEVA) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-RA-BR-105214-1 Risk Assessment generated by a regulatory process Risk Assessment of a biological product for veterinary use, namely VECTORMUNE® FP-LT+AE- Fowl Pox and avian Laryngotracheitis vaccine and avian encephalomyelitisVECTORMUNE® FP-LT + AE Vaccine | FOWPV, Production of medical or pharmaceutical compounds (human or animal)
